SCHEMBL20568433

SCHEMBL20568433

CCOC(=O)c1[nH]c2c(C3CC3)nn(C)c2c1-c1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.42
POLB P06746 2/20 0.42
MAPT P10636 3/20 0.40
KDM4E B2RXH2 2/20 0.38
HPGD P15428 2/20 0.38
TP53 P04637 1/20 0.38
HTT P42858 1/20 0.38
TRPC3 Q13507 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TRPC7 Q9HCX4 1/20 0.38
CHRNA7 P36544 1/20 0.38
CCR3 P51677 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRB2 P47870 1/20 0.38
TSHR P16473 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MDM2 Q00987 2/20 0.37
MDM4 O15151 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20568514 0.85 PRKAA2 (0.37) MAPTMAPK14
SCHEMBL20568849 0.84 PDE4A (0.47) LMNAPOLBMAPTHPGDHSD17B10
SCHEMBL20569603 0.82 LMNA (0.42) LMNAPOLBMAPTKDM4EHPGD
SCHEMBL20569633 0.81 LMNA (0.44) LMNAPOLBMAPTKDM4EHPGD
SCHEMBL20570104 0.76 LMNA (0.43) LMNAPOLBMAPTKDM4EHPGD
SCHEMBL18919805 0.74 POLB (0.44) LMNAPOLBMAPTKDM4EHPGD
SCHEMBL29569339 0.74 POLB (0.44) LMNAPOLBMAPTKDM4EHPGD
SCHEMBL1720599 0.69 HSD17B10 (0.52) LMNAMAPTKDM4EHPGDTP53
SCHEMBL23351434 0.69 PDE4A (0.56) LMNAPOLBMAPTHPGDHTT
SCHEMBL29568539 0.69 RPA1 (0.55) LMNAPOLBMAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210137886-A1 INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2021-05-13 US disclosed
US-20210137886-A1 INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2021-05-13 US disclosed
EP-3630777-A1 INHIBITORS OF METALLO-BETA-LACTAMASES Oxford University Innovation Limited (GB) 2020-04-08 EP disclosed
WO-2018215800-A1 INHIBITORS OF METALLO-BETA-LACTAMASES OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2018-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210137886-A1 INHIBITORS OF METALLO-BETA-LACTAMASES MGAM, GAA, LCT LMNA 1214/4885POLB 212/4885MAPT 2131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.